Related Experiment Video
Updated: Aug 19, 2026

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method
Published on: April 18, 2019
Combined therapy with arbekacin and fosfomycin for methicillin-resistant Staphylococcus aureus infections
1Second Department of Internal Medicine, Fukuoka University, School of Medicine.
Abstract:
We examined the clinical efficacy of a combination of arbekacin and fosfomycin in the treatment of various methicillin-resistant Staphylococcus aureus (MRSA) infections. The combination of arbekacin plus fosfomycin displayed 65.4% (17/26) clinical efficacy and 65.4% (17/26) bacteriological efficacy. This combination thus appeared to be an effective regimen for the treatment of MRSA infections. However, its bacteriological efficacy against concomitant Pseudomonas aeruginosa strains was only 16.7% (1/6). In addition, in 4 episodes of superinfection involving P. aeruginosa strains developed during the combination therapy.
Related Concept Videos
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Endocarditis III: Medical Management
Acute Pyelonephritis II: Diagnostic Studies and Management
Mechanism of Antibiotic Resistance in MRSA
Antifungal Agents
Clinical Significance of Antibiotic Resistance

